top of page

Our Science

Genbioma probes the gut microbiome and converts that knowledge into fast-tracked metabolic solutions.

 

Drawing on a wealth of clinical evidence, our scientists map host-microbe interactions with deep omics, then couple high-throughput bioassays with predictive modelling to collapse research timelines from years to months.

 

This integrated approach retires weak leads early, slashes development risk and delivers -biotic ingredients that are mechanism-backed, manufacturing ready and poised for clinical success.

Platform.png

Product Development Platform

Genbioma has validated a development platform for rapid identification and functional profiling of new microbiome-based solutions

​​

 

​Cuts cost, risk and time to market

​

  • Array of validated assays for glucose, lipid and cardiovascular metabolism using C. elegans model.

  • Integrated metagenomics & metabolomics to unveil mode-of-action early.

  • Regulatory filters baked in: Safety, IP and regulatory checkpoints for early candidate de-selection.

  • Human Validation: Clinical Trials and Real-World Evidence

 

​

Platform.png

Health Solutions

​

Genbioma advances metabolic wellness with postbiotic ingredients that restores gut-microbiota balance to steady glucose, harmonise lipid profiles and support healthy weight.

​

These benefits have been consistently demonstrated across diverse pre-clinical models, real world evidence and clinical studies in hospitals.

Prediabetes

Prediabetes a metabolic condition where blood glucose rises above normal but hasn’t yet reached Type 2 diabetes range. Left unchecked, it often progresses to Type 2 diabetes, a lifelong condition. Managed early, prediabetes can frequently be reversed.​​​

​​

​

Type 2 Diabetes

Diabetes is a chronic metabolic disease characterized by elevated blood sugar levels which, with time, damages the heart, blood vessels, eyes, kidneys and nerves. Its most common type is Type 2 diabetes, which happens when the body becomes resistant to insulin or does not make enough insulin.

​

Currently, over 400 million people live with diabetes worldwide and about 1.5 million annual deaths are attributable to diabetes. The prevalence of the disease has been rapidly growing over the last decades.

​

​

Scientific Publications

Pediococcus acidilactici CECT 9879 (pA1c®) and heat inactivated pA1c® (pA1c® HI) ameliorate gestational diabetes mellitus in mice

Heat-inactivated Pediococcus acidilactici pA1c®HI maintains glycaemic control and prevents body weight gain in high-fat diet-fed mice

Pediococcus acidilactici (pA1c®) alleviates obesity-related dyslipidemia and inflammation in Wistar rats by activating beta-oxidation and modulating the gut microbiota

Pediococcus acidilactici CECT9879 (pA1c) Counteracts the Effect of a High-Glucose Exposure in C. elegans by Affecting the Insulin Signaling Pathway (IIS)

Pediococcus acidilactici pA1c® Improves the Beneficial Effects of Metformin Treatment in Type 2 Diabetes by Controlling Glycaemia and Modulating Intestinal Microbiota

Antidiabetic Effects of Pediococcus acidilactici pA1c on HFD-Induced Mice

Glucose‑lowering effects of a synbiotic combination containing Pediococcus acidilactici in C. elegans and mice

Caenorhabditis elegans as a Screening Model for Probiotics with Properties against Metabolic Syndrome.

bottom of page